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Osteosarcoma is the most common primary malignancy of bone in children, adolescents, and adults. Despite extensive surgery
and adjuvant aggressive high-dose systemic chemotherapy with potentially severe bystander side effects, cure is attainable in about
70% of patients with localized disease and only 20%–30% of those patients with metastatic disease. Targeted therapies clearly
are warranted in improving our treatment of this adolescent killer. However, a lack of osteosarcoma-associated/specific markers
has hindered development of targeted therapeutics. We describe a novel osteosarcoma-associated cell surface antigen, ALCAM.
We, then, create an engineered anti-ALCAM-hybrid polymerized liposomal nanoparticle immunoconjugate (α-AL-HPLN) to
specifically target osteosarcoma cells and deliver a cytotoxic chemotherapeutic agent, doxorubicin. We have demonstrated that
α-AL-HPLNs have significantly enhanced cytotoxicity over untargeted HPLNs and over a conventional liposomal doxorubicin
formulation. In this way, α-AL-HPLNs are a promising new strategy to specifically deliver cytotoxic agents in osteosarcoma.
1. Introduction
Osteosarcoma is the most common primary malignant neo-
plasm of bone in children and adolescents and is character-
ized by unregulated proliferation of primitive osteoid-pro-
ducing mesenchymal cells [1]. Prior to 1970, the prognosis
for patients with osteosarcoma who were treated with sur-
gery alone was a dismal 10%–20% overall survival. Though
aggressive surgeries would render most patients grossly
tumor-free, the vast majority would develop progressively
fatal metastatic disease within two years. This suggested that
at the time of their initial diagnosis clinically undetectable
tumor had already spread to distant sites inmost patients and
that effective systemic anticancer therapy was needed [2].
The development of neoadjuvant cytotoxic chemother-
apy regimens over the past three decades has dramatically
improved the fate of osteosarcoma patients. The addition
of multiagent regimens plus refinement in surgical resection
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has resulted in a 65%–75% long-term survival rate in
patients presenting with localized disease [3]. While this is
a substantial improvement, current multimodality therapy
still has significant shortcomings. First, the outlook remains
poor for patients with radiographically detectable metastases
at diagnosis or for those in whom the cancer recurs. Second,
while the currently utilized chemotherapy regimens are effec-
tive against osteosarcoma, they also wreak havoc on normal
cells that can result in acute and potentially life-threatening
complications. It is also now appreciated that exposure of
pediatric cancer patients to cytotoxic chemotherapy can
lead to secondary malignancies and other medical maladies,
decades after their tumor has been eradicated [4].
The long-sought goal of being able to preferentially
deliver anticancer therapy to tumors while sparing normal
cells could have a significant impact on the deficiencies of
current osteosarcoma treatment regimens. In this regard, the
use of nanoparticles as delivery vehicles appears promising.
Liposomes, unilamellar vesicles composed of natural and/or
synthetic lipids, have been a particularly intensively studied
system [5]. The problem of containment versus controlled
release of anti-cancer agents has been a challenge for
liposomal drug delivery. On the one hand, liposomes need to
be formulated to allow for efficient packaging of therapeutic
agents and stable containment of drug in a normal extracel-
lular environment. On the other hand, liposomes that have
localized to tumors need to be able to release their payload
in order to have a therapeutic effect. This latter attribute has
been particularly difficult to program into standard liposome
formulations [6, 7].
Many nanoparticle anti-cancer targeting strategies re-
quire identification of a marker that is expressed on the
surface of the tumor cell. In particular, tumor-associated
molecules that are expressed at higher levels than in normal
tissues are sought since nanoparticles coated with antibodies
recognizing these markers can preferentially bind to tumor
cells. Finally from a potential therapeutic delivery perspec-
tive, it is best when candidate tumor markers are internalized
when bound by ligands or proteins at the cell surface [8]. By
exploiting this interaction, targeted nanoparticles can deliver
therapeutic payloads into tumor cells through receptor-
mediated endocytosis.
With these criteria in mind, the cell surface receptor
activated leukocyte adhesion molecule (ALCAM, CD166) is
an attractive candidate to target osteosarcoma. This glyco-
protein is a member of the immunoglobulin superfamily
and is thought to mediate important cell-cell interactions
involved in cell migration, neurogenesis, hematopoiesis, and
the immune response [9]. More recently, increased ALCAM
expression has been linked to a variety of cancers including
pancreatic, breast, prostate, and colorectal carcinomas and
melanoma [10–12]. Furthermore, others have found that
immunoliposomes coated with a recombinant anti-ALCAM
monoclonal antibody were taken up by prostate cancer cell
lines expressing this antigen [13].
In this paper, we demonstrate that ALCAM is overex-
pressed in both osteosarcoma tumor-derived cell lines and
primary biopsy specimens. We show that this cell surface
molecule can be exploited to enhance binding and uptake
of nanoparticles by osteosarcoma cells. We present a new
polymerized liposome formulation consisting of a mixture
of lipids with saturated and diacetylene containing acyl
chains that when loaded with doxorubicin displays enhanced
cytotoxicity to osteosarcoma cells. Finally, we find that coat-
ing these hybrid liposomes with recombinant anti-ALCAM
antibody further improves cytotoxic killing of osteosarcoma
cell lines.
2. Methods
2.1. Materials. Conventional and polymerized liposomal
nanoparticles (PLNs and HPLNs) were obtained from
NanoValent Pharmaceuticals, Inc. (Bozeman, MT, USA).
The components comprising the conventional liposomes are
L-α-phosphatidylcholine hydrogenated soy, (hydrogenated
soy PC), cholesterol and 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-N-[methoxy(polyethylene glycol)-2000]
(m-PEG2000-DSPE), (Avanti Polar Lipids, Alabaster, AL,
USA). The PLNs are comprised of (5′-hydroxy-3′-oxy-
pentyl)-10-12-pentacosadiynamide (h-PEG1-PCDA), (5′-
sulfo-3′-oxypentyl)-10-12-pentacosadiynamide (sulfo-
PEG1-PCDA), N-[(methoxy(polyethylene glycol)-750]-10-
12-pentacosadiynamide (m-PEG750-PCDA) and N-[(male-
imide(polyethylene glycol)-1500]-10-12-pentacosadiyn-
amide (mal-PEG1500-PCDA) (NanoValent Pharmaceuticals,
Inc. Bozeman, MT, USA) and the HPLNs are comprised h-
PEG1-PCDA, hydrogenated soy PC, m-PEG2000-DSPE, 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleim-
ide(polyethylene glycol)-2000] (mal-PEG2000-DSPE) (Avanti
Polar Lipids, Alabaster, AL, USA), and cholesterol.
2.2. Preparation of Conventional Liposomes and HPLNs.
Conventional liposomes were prepared from hydrogenated
soy PC, cholesterol, and m-PEG2000-DSPE in molar pro-
portions of 57.5 : 37.5 : 5, nontargetable HPLNs prepared
from h-PEG1PCDA, hydrogenated soy PC, cholesterol, and
m-PEG2000-DSPE at a molar proportion of 15 : 47 : 32 : 6,
and targetable HPLNs prepared from h-PEG1PCDA, hydro-
genated soy PC, cholesterol, mal-PEG2000-DSPE, and m-
PEG2000-DSPE at a molar proportion of 15 : 47 : 32 : 4.5 : 1.5,
and the PLNs prepared from h-PEG1-PCDA, m-PEG750-
PCDA, sulfo-PEG1-PCDA and mal-PEG1500-PCDA at a
molar proportion of 65 : 25 : 5 : 5, according to the method
previously described [14]. Briefly, lipids were mixed and
evaporated in vacuo, to a film. Deionized water or 300mM
ammonium sulfate was added to the films so as to give a
25mM (total lipid and cholesterol) suspension. The suspen-
sion was heated via sonication between 70 and 80◦C with a
probe-tip sonicator (Fisher sonic dismembrator model 300)
for 5min. The resulting milky solution was then passed
through a stacked polycarbonate membrane (100 nm), elev-
en times, with a dual syringe extruder (LiposoFast-Basic,
Avestin, Inc., Ottawa, ON, Canada), heated to 65◦C. The
nearly clear liposome solutions were cooled to 5◦C for 12
hours. After warming to ambient temperature, the water-
filled liposomes that contain PCDA lipids were polymerized
by UV light irradiation (254 nm) with a Spectrolinker
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XL-1000 UV Crosslinker (Spectronics Corp.) for 10 minutes.
The resulting blue PLNs and HPLNs were heated to 65◦C
for 5min to convert them to the red (fluorescent) form.
The colored solutions were syringe filtered through 0.2 μm
cellulose acetate filters in order to remove trace insoluble
contaminants.
2.3. Doxorubicin Loading. The ammonium sulfate-contain-
ing conventional and polymerizable (HPLN) liposomes was
passed over a G50 Sephadex column (washed with 20mM
HEPES) to exchange the external buffer. The liposomes were
then incubated with doxorubicin HCl (Shandong Tianyu
Fine Chemical Co., Ltd.) at a concentration of 1 μM of Dox
to 3.2 μM of lipid while heating to 65◦C for 20min. The
unencapsulated doxorubicin was removed by shaking with
anionic exchange resin (Bio-Rex 70, Bio-Rad Inc) in a ratio
of 7 μg of doxorubicin to 1 μL of packed resin, for 5min.
Liposomes were separated from resin by filtering through
Pierce Spin Cups. The average particle size measurements
were obtained on a Zetasizer Nano S (Malvern Inst.), in a
solution of 10mM sodium chloride.
2.4. Preparation of ALCAM-Antibody-Conjugated PLNs and
HPLNs. An anti-ALCAM antibody was previously engi-
neered into a cys-diabody (cross-paired dimer of single-
chain antibody fragments, with C-terminal cysteine residues)
as described [19]. PLNs and non-crossslinked, dox-loaded
HPLNs, were incubated with anti-ALCAM cys-diabody was
conjugated to the particle surface. TCEP (500mM) that
became added to cys-diabody (1–4 μg/μL) solution to a final
concentration of 10mM and incubated at room temperature
for 30 minutes to reduce the diabody’s terminal cysteine
residues. Reduced α-ALCAM cys-diabody was then added to
the liposome mixture (2.5–10 μg/μL lipid) at a diabody/lipid
ratio of 1 μg diabody : 7.5 μg total lipid and incubated at
room temperature for 2 hours to allow for conjugation
to maleimide residues on either the PLN or HPLNs.
Unbound maleimide residues were quenched with 20mM
cysteine solution for 30 minutes. Unbound diabody, free
cysteine, and TCEP were removed using filtration through
Amicon Ultra-0.5mL 100K Centrifugal Filters (Millipore).
Samples were diluted 1 : 2 with HEPES-buffered saline and
centrifuged at 6000 rpm for 10 minutes to concentrate the
ALCAM diabody conjugated sample. After purification the
antibody-conjugated, dox-loaded, non-crosslinked HPLNs
were photopolymerized by UV irradiation as described in
Section 2.1. The untargeted PLNs were prepared as controls
by quenching the maleimide residues with 20mM cysteine.
2.5. Quantification of Entrapped Liposomal Doxorubicin.
Doxorubicin was quantified spectrophotometrically based
on the molar extinction coefficient of 12,500. Unencap-
sulated Dox was removed using Bio-Rex 70. Dox-loaded
particles were disrupted using diluted a 1 : 20 isopropanol
with 0.075M HCl solution and then vortexed for at least 30
seconds to ensure complete membrane rupture. Absorbance
was read at 480 nm on a Beckman Coulter DU800 spec-
trophotometer.
2.6. Quantification of Total Lipid. Total lipid content of
HPLN samples was measured using a colorimetric assay. A
4 μL aliquot of HPLN sample was vacuum dried and resus-
pended in an ammonium ferrothiocyanate/chloroform
solution consisting of 0.1M Ferric chloride mixed with
0.4M ammonium thiocyanate and 200 ul of chloroform.
Absorbance at 488 nm of the organic phase was then meas-
ured in a Beckman Coulter DU800 spectrophotometer.
OD488 of the sample was then compared to a standard curve
of known lipid concentration values.
2.7. Stability of Liposomal Doxorubicin Containment. The
ability of nanoparticles (both HPLN and conventional lipo-
some formulation) to hold on to entrapped doxorubicin was
measured using a postload time course study. Nanoparticles
were loaded with doxorubicin using the procedure previously
described. After loading, several conditions of nanoparticle
storage were altered to simulate neutral pH of intracellular
environment and early and late endosome cellular compart-
ments. Nanoparticles were stored at a pH of 4.5, 6, or 7.4
and at temperature of either 4◦C or 37◦C giving a total of six
different storage conditions. The concentrations of doxoru-
bicin inside the nanoparticles were measured at 0 hr, 0.5 hr,
4 hr, 24 hr, 48 hr, and 144 hr using the method described
previously. Before each measurement, any extraliposomal
doxorubicin was removed by incubation with BioRex 70 resin
(Bio-Rad, Inc.). Each measurement was then normalized
to the time-zero measurement of the respective sample to
obtain a “percent-contained” doxorubicin measurement in
order to assess the stability of the particles. Analysis of
variance using log transformed data and blocking on experi-
ment day was used to assess the effect of vehicle, pH, and
temperature on doxorubicin leakage, to test for interactions
among factors, and to construct 95% confidence intervals for
geometric mean fold changes in leakage.
2.8. MTT Assay. Osteosarcoma cell lines KHOS 240S,
HOS, or MNNG-HOS were grown in Dulbecco’s Modi-
fied Eagle Medium (HyClone Cat no. SH30022.01) with
10% fetal bovine serum (Gemini Bioproducts). Cells were
seeded in a 96-well format at a concentration of 5 ×
103 cells/well at a volume of 100 μL media with peni-
cillin/streptomycin and incubated overnight. The following
day, wells were treated with doxorubicin-loaded targeted
HPLNs, untargeted HPLNs, conventional liposomes, or free
doxorubicin for a four-hour period then washed with fresh
media. Doses were added based on doxorubicin concentra-
tions ranging on a log scale from 0.01 to 100 μMand at 0 nM.
The 0 nM well was treated with HEPES-buffered saline. Each
treatment was performed in triplicate. Cells were incubated
under standard CO2 conditions for 72 hrs at 37◦C. At 72 hrs,
all wells are treated with 10 μL of thiazolyl blue tetrazolium
bromide (Sigma) solution at an initial concentration of
5 μg/μL in phosphate buffered saline and incubated for 4 hrs.
Reaction was ceased and cells lysed by adding 100 μL of 15%
sodium dodecyl sulfate/15mM HCl solution and incubated
overnight in the dark at room temperature. Plate absorbance
was read using Bio-Rad microplate reader at 570 nm. To
account for background absorbance, the arithmetic mean
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of the OD570 of the blank wells was subtracted from the
OD570 readings of all treated wells. The arithmetic mean of
each plate was calculated and considered as 100% viability.
The remaining wells were then divided by this mean to
obtain nominal percent viability within each well. Viability
was plotted against log drug concentration, and unweighted
nonlinear regression was used to estimate log (IC50) for each
treatment using a four-parameter sigmoid dose-response
model (Prism Software, GraphPad). Fixing the bottom
parameter to zero yielded better residual patterns and more
stable Hill slope estimates than analyses allowing a variable
bottom. For each cell line experiment, a run comparing
the four treatment vehicles was repeated 3 to 7 times on
different days. Within each cell line, a linear mixed effects
model revealed day-to-day variability as a much greater
source of variation in log (IC50) than batch variability,
and blocking on experiment day improved the precision of
estimated differences between treatments. In assessing IC50
results across cell lines, a significant cell line by treatment
interaction was detected that could be fully accounted for by
modeling a shift in conventional liposome potency (relative
to the other 3 treatments) just in the MNNG-HOS cell line.
2.9. PLN Binding Fluorescent Microscopy Assay. Osteosar-
coma cell lines were seeded onto 4-well Lab-Tek II Chamber
Slides (Thermo Scientific) to reach 80% confluence over-
night. Cells were treated with anti-ALCAM diabody con-
jugated PLN at 50 μg/mL per well. Cells were incubated
for 4 hrs at 37◦C. Media were removed, and wells were
washed with 1mL fresh media. Cell fixation was with 3.7%
formaldehyde in Phosphate buffered saline for 15 minutes at
4◦C. Cells were mounted using VECTASHIELD mounting
medium with DAPI (Vector Laboratories). Positive and
negative control cell lines were pancreatic cell lines HPAF and
MiaPaca, respectively. Cells were viewed using a Carl Zeiss
Axio Imager D1 fluorescence microscope. Cells were viewed
at 20x magnification. DAPI was visualized through blue/cyan
filter. Bound nanoparticles were visualized using the rho-
damine filter at a 1 second exposure.
2.10. Western Immunoblot. Antibodies used for immunoblot
were monoclonal mouse anti-CD166 (Vector Laboratories,
Cat no. VP-C375) at a concentration of 1 : 400 and anti-
Actin C-11 (Santa Cruz Biotechnology, Cat no. sc-1615) at
a concentration of 1 : 3000.
2.11. Immunohistochemistry. Deidentified human patient
osteosarcoma paraffin-embedded samples were obtained
from the UCLA Tissue Procurement Core Laboratory (IRB
Exempt). Four-micrometer sections were cut and placed
onto slides. Samples were then deparaffinized, rehydrated,
and subjected to heat-induced epitope retrieval. Slides were
incubated with a 1 : 50 dilution of anti-CD166 mouse
monoclonal antibody (Vector) for 2 h at room temperature,
and signal was detected using the mouse EnVision+ System-
HRP (DAB) kit (Dako). Sections were counterstained with
hematoxylin. Images were viewed and obtained using Zeiss
AxioImager at 20x magnification.
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Figure 1: ALCAM/CD166 is highly expressed in osteosarcoma cell
lines. Western immunoblot analysis of osteosarcoma cell lines prob-
ed with α-ALCAM antisera. There is high total cell expression of
ALCAM in HOS, KHOS, KHOS240s, and SJSA with moderate
expression in the MNNG-HOS cell line. A pancreatic cancer cell
line, HPAF, with known high levels of ALCAM expression was used
as a positive control. MiaPaCa, a pancreatic cancer cell line with
known lack of ALCAM expression served as a negative control.
Membrane-localized ALCAM isoform is present at 105 kDa. β-
Actin was used as an internal loading control.
HOS KHOS KHOS240S HPAF
KHOS312H MNNG-HOS SJSA MiaPaCa
Figure 2: Surface ALCAM expression in osteosarcoma cell
lines. Fluorescent immunohistochemistry showing membranous
ALCAM expression in osteosarcoma cell lines in comparison to a
known ALCAM expressing pancreatic cancer cell line, HPAF (pos-
itive control), and ALCAM negative cell line, MiaPaCa. ALCAM
binding shown in red (Alexa Fluor 564) and nuclei counterstained
with DAPI (20x magnification).
3. Results
3.1. ALCAM Is Highly Expressed in Both Primary Osteosar-
coma Specimens and Tumor-Derived Cell Lines. A molecular
survey of the osteosarcoma cell line U2-OS demonstrated
expression of ALCAM on the surface of these cells [15].
These observations prompted a more in-depth investigation
of ALCAM expression in human osteosarcoma. Evaluation
of ALCAM expression in a collection of 6 tumor-derived
cell lines was used as an initial platform. Cell lysates were
harvested from subconfluent adherent cultures grown in tis-
sue culture and analyzed by immunoblot using anti-ALCAM
antisera. Pancreatic cancer cell lines with high (HPAF) and
no (MiaPaCa) ALCAM expression were used as controls.
All 6 osteosarcoma cell lines expressed ALCAM, and 5 of
6 demonstrated elevated expression at the level seen in the
HPAF control (Figure 1). The quality of ALCAM expression
was further confirmed in fluorescent immunohistochemistry
showing primarily a membranous, surface component to the
ALCAM expression in osteosarcoma cell lines (Figure 2).
Though there was a high frequency of ALCAM expres-
sion in our cell line collection, there is always a concern that
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Localized OS (patient A1) Localized OS (patient A3) Localized OS (patient A6)
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Figure 3: ALCAM expression in human osteosarcoma patient tumor samples. Immunohistochemistry studies in human paraffin-embedded
localized and pulmonary metastatic osteosarcoma samples show mild to strong expression of ALCAM (brown) both membranous and
cytoplasmic in appearance in comparison to normal human muscle and human lung. Tissues were counterstained with hematoxylin
(magnification 20x).
it may be due to a selection process inherent in creating
tumor-derived cell lines. In addition, differences in growth
conditions between in vivo in osteosarcoma patients and
in vitro in tissue culture may be responsible for changes in
ALCAM expression.
To address these concerns, human osteosarcoma tumor
samples both from primary and metastatic sites were assayed
for ALCAM expression by immunocytochemistry. Banked
anonymized patient specimens were fixed, sectioned, and
incubated with anti-ALCAM antisera. After washing, in situ
ALCAM expression was detected using a colorimetric assay
and evaluated by light microscopy. Tissues were graded as
strongly positive (+++), moderately positive (++), weakly
positive (+), or negative (−). All OS tumor samples stained
positively for ALCAM. Of 10 localized and metastatic OS
samples, 5 of the localized OS tissues stained weakly to
strongly positive for ALCAM and 5 of the metastatic OS
samples also had moderate to strong IHC staining. Osteosar-
coma cells demonstrated both cytoplasmic andmembranous
ALCAM expression (representative IHC images are shown in
Figure 3).
3.2. Anti-ALCAM Coupled Polymerized Liposomal Nanopar-
ticles Avidly Bind to Osteosarcoma Cell Lines. Polymerized
liposomes and hybrid polymerized liposomal nanoparticles
(PLNs and HPLNs) were evaluated as a potential therapeutic
delivery vehicle that could be targeted to osteosarcoma cells
expressing ALCAM. PLNs and HPLNs share many struc-
tural attributes of conventional liposomes. They are self-
assembling unilamellar spheres whose surfaces can be modi-
fied using the same chemical coupling strategies as employed
for liposomes. Unlike liposomes, PLNs and HPLNs can be
manufactured to be intrinsically fluorescent. Ultraviolet irra-
diation leads to cross-linking of diacetylene residues present
in their acyl chains, leading to highly colored blue particles,
and heat treatment of the PLNs and HPLN vesicles leads
to color change and fluorophore formation [16, 17]. The
fluorescence emission spectrum is centered at 635 nm with a
broad and complex excitation spectrum from 480 to 580 nm.
As a result, PLNs andHPLNs converted into their fluorescent
form can be readily traced from the time they bind to target
cells until they are deposited and compartmentalized into
subcellular structures.
Targeted PLNs and HPLNs were created by chemically
coupling a recombinant anti-ALCAM antibody fragment
to its surface. PLNs and HPLNs were synthesized con-
taining maleimide reactive groups at the distal end of
surface polyethylene glycol (PEG)molecules. A bivalent anti-
ALCAM diabody, derived from a previously described scFv
[18], was genetically engineered to contain a C-terminal
cysteine [19]. The resulting cys-diabody is bivalent, compact
(one-third the size of an intact antibody) and enables site-
specific oriented coupling of the antibody variable regions
to the surface of nanoparticles [20]. Mixing these two
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components induced a condensation reaction between the
thiol of the cysteine and the maleimide moiety, resulting
in the anti-ALCAM diabody being covalently coupled to
the PLN or HPLN surface. As a negative control, untar-
geted HPLNs where prepared without maleimide lipid and
untargeted PLNs were made by coupling free cysteine to
nanoparticles.
Binding studies were performed comparing the relative
affinities of anti-ALCAM coupled PLNs (α-AL-PLN) versus
untargeted PLNs towards osteosarcoma cell lines. After a 4-
hour incubation, cells were washed and (α-AL-PLN) binding
was detected by fluorescence microscopy. α-AL-PLNs bound
to all of the osteosarcoma cell lines in our panel, much more
efficiently than untargeted negative controls (Figure 4). This
interaction was dependent on cellular ALCAM expression.
Both targeted and untargeted PLNs bound equally to
MiaPaCa cells that do not express cell surface ALCAM.
To gauge the rapidity of the interaction between α-
AL-PLNs and osteosarcoma cells, a time course study was
performed. Osteosarcoma cells were incubated with α-AL-
PLNs for varying time periods up to 4 hours, washed, and
then evaluated by fluorescence microscopy.
α-AL-PLNs binding was detected as early as 30 minutes
and reached a maximum by 4 hours (Figure 5). The presence
of a strong perinuclear fluorescence signal suggested that
the targeted nanoparticles were rapidly internalized into the
endosome compartment of the cell. To further evaluate this,
binding studies were performed at 4◦C, which would inhibit
cellular endocytosis. Under these conditions, a strong mem-
brane fluorescence signal was detected without perinuclear
nuclear localization consistent with α-AL-PLNs being bound
to the cell surface but not internalized (Figure 6).
3.3. Hybrid PLNs Were Formulated to Function as Potential
Therapeutic Delivery Vehicles. Our initial PLN formula-
tion was composed entirely of 10,12-pentacosadiynoic acid
(PCDA) derivatives and when polymerized formed a very
fluorescent particle that could easily be detected. However,
these nanoparticles proved to be problematic when trying to
adapt them for delivery of therapeutics. Attempts at effec-
tively loading them with cytotoxic chemotherapeutic agents,
either through encapsulation during vesicle formation or
across ion gradients using the prepolymerized liposomes,
failed at multiple levels. For this reason, hybrid PLNs were
created which composed of PCDA lipids mixed with satu-
rated phospholipids found in many liposome formulations.
To approach this problem, we started with a standard
liposomal formulation consisting of hydrogenated soy PC
(where the major component is distearoylphosphatidyl-
choline (DSPC)), cholesterol, and polyethylene glycol-distea-
roylphosphatidyl ethanolamine (m-PEG2000-DSPE) in molar
proportions of 57.5 : 37.5 : 5. Increasing amounts of unsatu-
rated PCDA lipids were then added. We chose a very short
PEG chain PCDA derivative, h-PEG1-PCDA, because it is
an extremely reactive cross-linking lipid, has good aqueous
dispersion properties when mixed with charged lipids, and
is in itself uncharged so it will not alter the overall surface
charge, and the small polar head will not interfere with
the conjugation of targeting agents. After sonication and
PLN
targeted
(+)ALCAM
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KHOS240s MNNG-HOS MiaPaCa
Figure 4: α-ALCAM-targeted PLNs bind specifically to osteosar-
coma cell lines. α-ALCAM cys-diabody conjugated PLNs show
specific binding (red) to two osteosarcoma cell lines expressing
ALCAM, KHOS240s and MNNG-HOS. There was no binding to
a cell line that does not express ALCAM, MiaPaCa. Fluorescence
microscopy of PLNs is shown in red and DAPI nuclear counter-
staining in blue (magnification 20x).
0 hr 1 hr 2 hr 4 hr
PLN incubation time:
Figure 5: α-ALCAM-conjugated PLNs show cell-specific targeting
in a time-dependent manner. α-ALCAM-conjugated PLNs were
incubated with osteosarcoma cells for 0, 1, 2, and 4 hours then
washed off. α-ALCAM targeted PLNs bind specifically to the
ALCAM expressing osteosarcoma cell line KHOS240s at one hour
and reach a maximum binding at 4 hours of incubation. Flu-
orescence microscopy of PLNs (shown in red) with DAPI (blue)
nuclear counterstaining (magnification 20x).
PLN
targeted
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Figure 6: α-ALCAM-conjugated PLNs are internalized via re-
ceptor-mediated endocytosis. α-ALCAM-targeted PLNs incubated
with the osteosarcoma cell line KHOS240s at 4 degrees and at 37
degrees Celsius show inhibition of receptor-mediated endocytosis
at 4◦C and rapid internalization of targeted PLNs at 37◦C versus
untargeted PLNs that do not bind under either circumstance.
Fluorescence microscopy of PLNs (shown in red) with DAPI (blue)
nuclear counterstaining (magnification 20x).
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Figure 7: Containment of doxorubicin over time in drug-loaded liposomal vehicles. Containment studies of loaded HPLNs versus
conventional PEG-liposomes showed that leakage increased significantly with time (P < 0.0001), with geometric means at 4 hours, 1 day,
and 6 days being, respectively, 0.9%, 4.6%, and 3.1% for conventional doxorubicin-loaded PEG-liposomes and 1.2%, 3.2%, and 5.9% for
HPLN. There were no significant differences between the vehicles or the effects of pH or temperature that could be detected at 4 hours or 1
day. However, at 6 days HPLN had 1.9-fold greater overall leakage than DOX (P < 0.001; 95% C.I. 1.6- to 2.4-fold). Lowering pH from 7.4
to 4.5 increased leakage by a factor of 1.5 (P = 0.01; 95% C.I. 1.1- to 2.1-fold) with enhanced leakage at 37 degrees compared to 4 degrees
(P = 0.03).
extrusion, vesicles were evaluated for size by dynamic light
scattering and the ability to form fluorescent particles when
treated with UV irradiation and heat. After overnight cooling
to 5◦C, we found that inclusion of as little as 15 mole%
h-PEG1-PCDA resulted in brightly blue-colored particles
but that this color became progressively attenuated with
decreasing h-PEG1-PCDA proportions.
Considering that our HPLNs were a heterogeneous mix
of lipids with two very different acyl chain structures, stabil-
ity in solution was a major concern. Certain hybrid form-
ulations formed insoluble aggregates within hours after
extrusion. Overnight cooling at 5◦C immediately after extru-
sion, but prior to polymerization, proved to be critical in
creating stable HPLNs. Particles treated this way were stable
for weeks either refrigerated or at room temperature. Hybrid
PLNs of the same lipid composition constructed without this
cooling step were irretrievably unstable.
From these studies, an optimized HPLN formulation
was empirically derived consisting of h-PEG1-PCDA, hydro-
genated soy phosphatidylcholine, DSPC, cholesterol, and m-
PEG2000-DSPE at a molar proportion of 15 : 47 : 32 : 6. Using
this formulation, HPLNs were fabricated and their ability
to be actively loaded with doxorubicin through generation
of an ion gradient was assessed [21]. Using this method,
doxorubicin could be loaded into HPLNs to an average
final drug/lipid molar ratio of 0.15 (range 0.13–0.18) in
comparison to conventional PEG-liposomes lacking PCDA
lipids which could be loaded to an averagemolar ratio of 0.44
(range 0.35 to 0.49).
Containment studies of loaded HPLNs versus con-
ventional PEG-liposomes showed that leakage increased
significantly with time (P < 0.0001), with geometric means
at 4 hours, 1 day, and 6 days being, respectively, 0.9%,
4.6%, and 3.1% for conventional doxorubicin-loaded PEG-
liposomes and 1.2%, 3.2%, and 5.9% for HPLN (Figure 7).
No significant differences between the liposomal vehicles or
the effects of pH or temperature could be detected at 4 hours
or 1 day. However, at 6 days at 37 degrees HPLN had 1.9-fold
greater overall leakage than DOX liposome at either 4 or 37
degrees (P < 0.001; 95% C.I. 1.6- to 2.4-fold). In addition,
lowering pH from 7.4 to 4.5 increased drug release in HPLN
by a factor of 1.5 (P = 0.01; 95% C.I. 1.1- to 2.1-fold)
with evidence that this effect was enhanced at 37 degrees
compared to 4 degrees (P = 0.03).
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3.4. Untargeted Doxorubicin-Loaded HPLNs Are More Cyto-
toxic to Osteosarcoma Cells Than Liposomal Doxorubicin For-
mulations. Since doxorubicin is a mainstay in the current
treatment of osteosarcoma, it was chosen as our initial
payload to test whether HPLNs could serve as therapeutic
delivery vehicles. HPLNs and conventional liposomes were
fabricated by the same procedure of hydration of dried
lipid films by brief sonication followed by extrusion through
100 nm polycarbonate filters. The sizes of HPLNs and lipo-
somes were approximately the same varying from batch to
batch from 90 to 110 nm with a typical polydispersity index
of about 0.1. Both particles were loaded with doxorubicin
using ammonium sulfate gradients. Prior to dosing cells,
loaded nanoparticles were incubated briefly with an anionic
exchange resin (BioRex 70, BioRad Inc) to scavenge any
nonencapsulated (free) doxorubicin. This ensured that cells
were not exposed to free drug that may have leaked out
while particles were in storage. Nonconfluent osteosarcoma
cell lines were then incubated for 4 hours with varying
concentrations of doxorubicin-loaded HPLNs or liposomes
in triplicate. Cells exposed to free doxorubicin (DOX) served
as positive controls. After dosing, cells were washed with
fresh media and incubated for a total of 72 hours. Cell
viability was then quantified by MTT assay, and 50% inhi-
bitory concentrations (IC50s) were estimated. For each ost-
eosarcoma cell line, this experiment was performed 3–7
times using at least two different batches of HPLNs and
liposomes.
Absolute IC50 values for each doxorubicin prepara-
tion varied according to osteosarcoma cell line (Figure 8).
However, the trend reflecting the relative potency of these
preparations was consistent across all cell lines tested. As has
been seen previously in other cell models, free doxorubicin
was approximately 38- to 82-fold more potent than conven-
tional liposomal doxorubicin [22]. Loaded HPLNs without
targeting (HPLN/Dox) showed intermediate potency that
was about 6-fold greater than the conventional PEGylated
liposomal preparation.
Follow-up experiments were performed to determine
whether the increased growth inhibition mediated by loaded
HPLN/Dox was related to the amount of PCDA lipid in
this formulation. HPLN/Dox with reduced PCDA were
fabricated, loaded, and incubated with the KHOS240S osteo-
sarcoma cell line. Though these variant HPLN/Dox formula-
tions were of similar size and loaded equally well with dox-
orubicin, decreasing the PCDA lipid composition resulted
in nanoparticles with decreased growth inhibitory potency
(data not shown).
3.5. ALCAM Targeting Enhances the Growth Inhibitory Effect
of Doxorubicin-Loaded PLNs. We have shown that coupling
anti-ALCAM diabodies to the surface of PLNs increases their
binding affinity for osteosarcoma cell lines (Figure 4). This
same effect was found using α-AL-HPLNs (data not shown).
Experiments were then performed to determine whether
this targeting function improved the ability of doxorubicin-
loaded HPLNs to inhibit growth of osteosarcoma cell lines.
Targetable HPLNs were fabricated using h-PEG1-PCDA,
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Figure 8: Cytotoxicity IC50s for doxorubicin-loaded vehicles and
free DOX. Targeted and untargeted hybrid PLNs were incubated
with osteosarcoma cell lines in comparison to free doxorubicin
and conventional PEG-liposomal doxorubicin. Mean log IC50 for
osteosarcoma cell lines shows that untargeted hybrid PLNs have a
6-fold increase in cytotoxicity over conventional liposomal formu-
lation. ALCAM targeted hybrid PLNs (HPLN) show an additional
2-fold increase over untargeted HPLNS and 12-fold increase in
cytotoxicity over conventional PEG-liposomal doxorubicin. Geo-
metric mean IC50s were derived from seven, five, and three sets
of MTT assay experiments in, respectively, the KHOS240s, HOS,
and MNNG-HOS cell lines. Error bars correspond to 1 standard
error for mean log (IC50). Within each cell line, differences among
vehicles are highly significant (P < 0.0001). Confidence intervals
for pairwise ratios of IC50s, corrected for multiple comparisons, are
summarized in Table 1.
hydrogenated soy phosphatidylcholine, cholesterol, Mal-
PEG2000-DSPE, and m-PEG2000-DSPE at a molar ratio of
15 : 47 : 32 : 4.5 : 1.5. The proportion of maleimide DSPE was
empirically determined as the lowest amount that when
coupled to anti-ALCAM diabody would result in enhanced
binding to osteosarcoma cells (data not shown). After load-
ing with doxorubicin, HPLNs were coupled to anti-ALCAM
diabody as before giving α-AL-HPLN/Dox. Osteosarcoma
cells were then incubated with α-AL-HPLN/Dox as previ-
ously described.
As seen with untargeted hybrids, the absolute sensitivity
to α-AL-HPLN/Dox varied across different osteosarcoma
cell lines (Table 1). However, in all cases, the targeted HPLNs
demonstrated an additional growth inhibitory potency over
untargeted HPLN counterparts of approximately 2-fold in all
cell lines (Figure 8). Taken together, α-AL-HPLN/Dox had a
log order (12-fold) increase in cytotoxicity over the conven-
tional untargeted PEG-liposomal doxorubicin formulation
in KHOS240s and HOS cell lines while having a 23-fold
increase in the chemoresistant MNNG-HOS cell line. This
implies that α-AL-HPLN/Dox can both specifically bind cells
and deliver doxorubicin to achieve greater cytotoxicity over
a conventional untargeted liposomal nanoparticle formula-
tion.
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Table 1: Relative cytotoxic potency of doxorubicin-loaded vehicles: ratio of (IC50)−1 between vehicles summarized by geometric mean (95%
confidence interval)a.
Osteosarcoma cell line
Untargeted HPLNs Targeted HPLNs Targeted HPLNs Free Dox
over over over over
conventional liposomes untargeted HPLNs conventional liposomes targeted HPLNs
KHOS240s 5.4 (3.7–8.0) 2.3 (1.5–3.3) 12.2 (8.3–18.0) 3.1 (2.1–4.6)
HOS 7.0 (4.8–10.1) 1.7 (1.1–2.4) 11.6 (8.0–16.8) 3.1 (2.1–4.5)
MNNG-HOS 11.4 (5.4–23.9) 2.0 (0.95–4.2) 22.8 (10.8–47.8) 3.6 (1.7–7.5)
Summary of all 3 linesb, c 5.9c (4.6–7.6) 2.0 (1.6–2.5) 11.8c (9.2–15.2) 3.2 (2.6–4.1)
aTukey HSD 95% confidence intervals for multiple comparisons in each cell line.
bBased on linear mixed effects model for log IC50 as a function of cell line and vehicle.
cIndicated potency ratio is 2.0-fold greater (95% CI: 1.4–2.8) in MNNG-HOS cell line, consistent with significant cell line by vehicle interaction (P = 0.015).
4. Discussion
Our data clearly demonstrate an increase in ALCAM expres-
sion in osteosarcoma though the biologic consequences of
this are difficult to gauge. The normal physiologic roles of
ALCAM are still coming to light, but its molecular structure
and clustering at tight junctions suggest that it could be
involved in cell adhesion and migration [23]. In this context,
it is tempting to think that modulating ALCAM expression
could potentiate the invasive and metastatic behaviors found
in high-grade malignancies such as osteosarcoma. However,
there is no consistent correlation between ALCAM expres-
sion level and patient survival across all cancers. For example,
an increase in ALCAM expression is found in higher-stage
more aggressive malignant melanoma [24]. By contrast, high
ALCAM is correlated with low-grade less aggressive cases
of prostate cancer [11]. Considering the high frequency of
elevated ALCAM expression in even our small cohort of
osteosarcomas, it may not be able to discriminate between
high- and low-risk patients with this disease.
Though ALCAM may be a limited prognostic biomarker
in osteosarcoma, it has potential to serve as a molecule
through which to therapeutically target this tumor. Fluo-
rescent nanoparticles coated with anti-ALCAM diabodies
preferentially bind to osteosarcoma cell lines, even those that
express ALCAM at relatively low levels. As seen in prostate
cancer cells, ALCAM-targeted nanoparticles were rapidly
internalized by osteosarcoma cells suggesting a strategy for
intracellular delivery of anticancer agents.
The use of diacetylene containing lipids to create poly-
merizable films and vesicles has been intensively studied for
creating biosensors [25] and have been explored as cancer
diagnostic and delivery vehicles [26]. When these mem-
branes are treated with ultraviolet irradiation the resulting
intralipid cross-links form an intensely blue chromophore.
When exposed to physiochemical perturbations such as heat,
shear, or pH stress, these membranes shift from a blue
nonfluorescent state to a red fluorescent state [17]. A distinct
advantage to the HPLN fluorescence is that little or no
photobleaching occurs. Taking advantage of these properties,
we were able to track binding and internalization of red,
fluorescent ALCAM-targeted PLNs (α-AL-PLN) that had
been treated with UV irradiation and heat. Interestingly,
we obtained the same results using a similar preparation
of α-AL-PLN that received only UV irradiation and were
therefore blue and nonfluorescent in solution (data not
shown). It appears that the interaction between the coupled
diabody molecules and the cell surface ALCAM proteins
exerted sufficient stress to shift the bound α-AL-PLN into a
fluorescent state.
Though vesicles composed entirely of diacetylene con-
taining lipids had excellent detection properties, they had
limited capability as therapeutic delivery vehicles. We were
unable to stably load these liposomes with doxorubicin
either by passive encapsulation during vesicle formation or
actively across ion gradients in formed vesicles. Others have
been able to passively load hybrid liposomes composed of
a 1 : 1 mixture of a phosphatidylcholine derivative with a
dichain diacetylene lipid and another phospholipid [27].
However, loading efficiencies were low and this strategy may
be limited to hydrophobic payloads. We have found that for
amphiphilic molecules such as doxorubicin, in HPLNs, with
single-chain, neutral PCDA lipids the polymerizable lipid
concentration needs to be 20mole percent or less for efficient
loading to occur (data not shown).
Though our HPLNs were initially formulated for their
stable drug loading characteristics, they surprisingly also
proved to be more therapeutically potent in in vitro testing.
The IC50 concentrations of untargeted doxorubicin-loaded
hybrid PLNs in three independent osteosarcoma tumor-
derived cell lines were at least 6-fold lower than conventional
liposomal doxorubicin composed of PEGylated saturated
phospholipid. This boost in potency appears to depend
on PCDA lipid content since it is progressively lost as the
PCDA concentration is titrated down from an optimum
of 15–20 mole percent (data not shown). From this point,
the lower the PCDA lipid concentration is in our HPLNs,
the higher the IC50 becomes in our osteosarcoma model.
Recently, others have used mixtures of diacetylene lipids and
phospholipids to create liposomes that could be selectively
destabilized either by photochemical means or by thermal
shock [28, 29]. The goal here was to create a therapeutic
vehicle that would release its payload in a temporal spatially
controlled fashion.
We have found that even without applying an external
destabilizing stimulus, HPLNs can be more effective ther-
apeutic delivery vehicles than standard liposomal formula-
tions. The mechanisms underlying this effect are unclear and
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require further investigation. The presence of PCDA in our
hybrid formulations could be having an effect at multiple
steps in our in vitro assay from (i) nanoparticle binding to
cells to (ii) cellular uptake to (iii) intracellular release of
cytotoxic payload. This last step in particular may be rate
limiting. The roughly 50-fold difference in IC50 between free
doxorubicin and conventional liposomal doxorubicin seen in
our osteosarcoma cell lines is consistent with that found in
previously publishedmodel systems [22]. Others have shown
that this is primarily due to delayed release of free drug
from the endocytic compartment of cells that have taken up
liposomal doxorubicin [30].
Evaluating the stability of doxorubicin drug contain-
ment within the HPLN versus conventional PEG-liposomes
showed that there was a statistically significant increase in
doxorubicin release from the HPLN over time. Furthermore,
this enhanced drug release was accentuated under acidic
conditions mimicking the receptor-mediated endocytic envi-
ronmental conditions of late endosomes and lysosomes. It is
tempting to hypothesize that the PCDA lipids may enhance
the release of doxorubicin from HPLNs that have been
taken up by osteosarcoma cells. Given their differences in
molecular structure, it is highly likely that microsegregation
occurs between PCDA lipids and phospholipid molecules
on the surface of HPLNs. Evidence found in published
studies with similar mixtures of longer chain diacetylene
lipids and shorter chain phosphatidylcholine lipids suggests
that a phase separation occurs between the lipid types [31].
It is possible that these PCDA lipid islands could serve as
destabilization points that could enhance drug release when
exposed to intracellular environments.
The creation of an osteosarcoma-targeted doxorubicin
loaded HPLN (α-AL-HPLN/Dox) resulted in a 2-fold
increase in cytotoxicity over the untargeted HPLN/Dox and
a 12-fold increase in cytotoxicity over the conventional
PEG-liposomal formulation in the HOS and KHOS240s
osteosarcoma cell lines. These results suggest that ALCAM
targeting in osteosarcoma adds an incremental therapeutic
effect. Interestingly, in the MNNG-HOS cell line the α-AL-
HPLN/Dox had an even greater increase (23-fold) in cyto-
toxicity over the PEG-liposomal formulation. The MNNG-
HOS cell line has high expression levels of the multidrug
resistant protein 1 (MDR1) conferring chemotherapeutic
resistance to doxorubicin [32]. The increased sensitivity
of the MNNG-HOS chemoresistant cell line to the α-AL-
HPLN/Dox formulation over the conventional formulation
points to a therapeutic effect that may overcome multidrug
resistance. We can hypothesize that the targeting and
improved sustained drug release characteristics of our α-AL-
HPLN/Dox formulation may help to bypass or overwhelm
the drug efflux proteins mediating chemoresistance thereby
improving cytotoxicity.
In conclusion, we have found a novel surface marker
in human osteosarcoma, ALCAM, which we have used to
specifically target osteosarcoma cells with a novel engi-
neered drug-loaded hybrid PLN formulation anti-ALCAM
immunoconjugate. These α-AL-HPLN/Dox particles show
improved cytotoxicity over a conventional untargeted PEG-
liposomal doxorubicin formulation and show promise as
a potential therapeutic delivery platform in osteosarcoma.
This new liposomal nanoparticle formulation is particularly
attractive for its potential therapeutic application in resistant,
refractory, and metastatic osteosarcoma where current stan-
dard systemic untargeted chemotherapy is generally not effi-
cacious and prognosis is dismal. Furthermore, the bystander
and dose-limiting side effects of systemic chemotherapy
are substantial. Thus far this formulation has only been
tested in tissue culture based assays, so further assessment in
tumorigenic animal models is a crucial next step to validate
these findings. These experiments are currently under way.
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